MindBio Therapeutics Completes Intox Collect(TM) Platform to Scale AI Voice-Based Intoxication Detection

MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) has announced the completion of its Intox Collect(TM) technology, a development that enables rapid scaling of data collection and analysis across a wide range of substances using voice and facial recognition. This platform enhances the company's ability to train its artificial intelligence model, which leverages more than 50 million data points to predict drug and alcohol intoxication through voice with high accuracy. The biotechnology company focuses on AI-driven voice analytics for intoxication detection, and this advancement supports its expansion into regulated industries such as mining, aviation, construction, and law enforcement.

The Intox Collect(TM) technology represents a significant step toward commercialization, with upcoming Edge AI kiosk devices expected to begin testing in the second quarter of 2026. These kiosks will integrate bespoke hardware and software for detecting drug and alcohol intoxication using the human voice and AI in various enterprise environments. The company's AI prediction model is designed to identify intoxication with remarkable accuracy solely through voice analysis, making it a potentially valuable tool for safety-critical industries where impairment can lead to serious accidents or operational failures.

This development matters because it addresses a growing need for reliable, non-invasive methods to detect substance impairment in workplace settings. Traditional methods like breathalyzers or blood tests can be intrusive, time-consuming, and limited in scope, whereas voice-based analysis offers a more seamless approach that could be integrated into daily operations without significant disruption. The technology's ability to analyze over 50 million data points suggests a robust training foundation that could improve detection reliability across diverse populations and substance types.

The implications of this announcement extend beyond technological achievement to potential regulatory and safety applications. In industries like mining and aviation, where impairment poses severe risks, implementing such detection systems could enhance workplace safety protocols and help prevent accidents. The move toward Edge AI kiosks indicates a practical deployment strategy that brings the technology directly to point-of-need locations rather than relying on centralized analysis. As MindBio Therapeutics advances toward commercialization, the Intox Collect(TM) platform could establish new standards for intoxication monitoring in professional environments. For more information about the company's developments, visit https://ibn.fm/MBQIF.